At the interface between immunology, computer science and machine learning, Evaxion leads an engineering-first approach to modeling the immune system. With a continuous sight towards saving and improving lives with Al-Immunology™, Evaxion counts on:

Interdisciplinary Collaboration and Data Mastery: Through an effective collaboration between our talented pool of bioinformaticians and immunologists, we excel in data acquisition, quality assessment, and innovative up-cycling to maximize data integrity and utility.

Technological Agility and Machine Learning Prowess: Harness the power of state-of-the-art machine learning (ML) algorithms and models, we provide the infrastructure needed to enhance the speed of iteration from idea to validation

Critical Evaluation and Clinical Applicability: Instills a culture of meticulous scrutiny for the validation and interpretation of AI predictions, underpinned by a steadfast commitment to clinical scalability and compliance, ensuring that AI-driven insights translate effectively to patient-centric solutions.

Our modern research facility specializes in in vivo models, providing a platform for real-life testing of AI-Immunology™ products. With the ability to swiftly screen in-silico predicted vaccines across numerous models, we emphasize following compliance requirements with the stringent Danish and European ethical standards. We have an animal welfare organ where ethics and replacement options are discussed in a forum of scientists, veterinarians and laymen.

In our cutting-edge vivarium, we merge technological advancement with a commitment to humane and responsible research, taking our time with the animals and using the best possible enrichment for animal welfare to ensure that our pursuit of scientific progress aligns with the highest ethical principles.

Pioneering personalized cancer vaccines through clinical trial testing, we have challenged what was believed to be possible and created a pipeline capable of manufacturing individualized cGMP vaccines based on each patient’s tumor signature. Our manufacturing capabilities are characterized by:

Streamlined Manufacturing Integration and Optimized Turnaround: Reduction of manufacturing Turn Around Time (TAT) from months to weeks by fostering interconnection between various manufacturing and QC testing stages and Contract Development and Manufacturing Organizations (CDMOs), complemented by tightly controlled shipment logistics. 

Adaptive Production and Distribution Platform: Robust plasmid DNA and peptide manufacturing platforms adept at managing an array of product and logistic variations, ensuring flexibility and responsiveness in production and supply chain operations.

Regulatory Acumen in Personalized Therapies: Extensive regulatory expertise in personalized therapies, with a proven track record navigating the FDA (US), EMA (EU) and TGA (AUS) regulatory frameworks, which reinforces our capacity to meet complex compliance mandates effectively.